To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles

1. Trends in practice of family planning: Varanasi (rural)
2. Tri-sectoral approach in managing the family planning program (labor aspect)
3. Tri-sectoral approach in managing the Family Planning Programme.
4. Trip report on Antigua to the International Planned Parenthood Federation/Western Hemisphere Region office.
5. A trip to the Philippines: in search of ways and means of cooperation, assistance in the field of population and family planning.
6. Tryptophan, depression and steroidal contraception.
7. Tubal ligations on general service patients seen by peer-level family planning counselors in thirty New York City voluntary and municipal hospitals.
8. Tunisia. (Family planning programs)
9. Tunisian legislation concerning family planning) [Legislation Tunisienne en matiere de planning familial.]
10. Turkey. (Family planning programs)
11. Twenty questions concerning the quarterly injection of prolonged-action contraceptives. [Vingt questions a propos de l'injection trimestrielle de conraceptif-retard.]
12. Twenty-five communication obstacles to the success of family planning programs.
13. Two oral contraceptives with the same gestagen and different estrogen: A controlled clinical trial. [To perorale antikonceptiva med samme gestagen og forskelligt oestrogen: En kontrolleret klinisk undersoegelse.]
14. U.S. organized family planning programs in FY 1974.
15. U.S. policies toward underdeveloped countries: the birth control alternative.
16. Ultrastructural aspects of the liver during treatment with oral contraceptives. [Aspetti ultrastrutturali del fegato in corso di trattamento con contraccettivi orali.]
17. Unilateral tubo-ovarian abscess and intrauterine contraceptive device.
18. Unsuspected pelvic infection discovered at tubal ligation: relationship to use of intrauterine contraception.
19. Unusual signs and symptoms associated with oral contraceptive medication.
20. Update on problems of oral contraceptives.
21. Urinary 4-pyridoxic acid, plasma pyridoxal phosphate, and erythrocyte aminotransferase levels in oral contraceptive users receiving controlled intakes of Vitamin B6.
22. Urinary corticosteroid sulfates in oral contraceptive users. (Abstract only)
23. Uruguay. (Family Planning Programs)
24. Use of a low-dose oral contraceptive preparation: report of a study.
25. The use of contraceptive pills in treatment of recurrent aphthous ulceration.
26. Acute ischemia of lower limbs with oral contraceptives. [Ischemies aigues des membres inferieurs sous contraceptifs oraux.]
27. Administration of hormonal contraceptives before menopause. [Die Verabreichung hormonaler Kontrazeptiva vor der Menopause.]
28. Administration of norethandrolone and testosterone as a contraceptive agent for men.
29. Administration of services: possible factors affecting method selection among Philippine family planning acceptors.
30. Administration, research and training in some Latin American and other family Planning programmes.
31. Administrative constraints in implementing national family planning programmes in the ESCAP region.
32. Adrenocortical function in progeny of rats treated with contraceptives.
33. The role of youths and youth organisations in family planning and population programme.
34. Ruptured benign hepatoma associated with an oral contraceptive.
35. Safety of contraceptive methods: amenorrhea.
36. Satisfactions and costs of children in family planning decisions of parents: a discussion guide for social work education.
37. School syllabus on family planning and population education. The role of teachers. Teaching methodology.
38. Scope of demographic research for population and family planning.
39. Screening oral contraceptive candidates: is the doctor dispensable?
40. Secondary amenorrhea after oral contraceptives: treatment and follow-up.
41. Selected bibliography (on audio-visual resources in population education and family planning)
42. Selected water soluble vitamin alterations associated with the use of oral contraceptive agents. (Abstract only)
43. Selection of a contraceptive method for a diabetic patient. [Choix d'une methode contraceptive chez la patiente diabetique.]
44. Selling family planning to the farmer.
45. Seminar/workshop recommendations. (Family planning services)
46. The separate effects of individual child loss, perception of child survival and community mortality level upon fertility and family planning in rural Taiwan upon comparison data from urban Morocco.
47. Serum activity of lysosomal enzymes in relationship to contraceptive steroid dose.
48. Serum immunoglobulins and C-reactive protein in patients using intrauterine contraceptive devices.
49. Serum lecithin:cholesterol acyltransferase (LCAT) levels and oral contraceptives. (Abstract only)
50. Serum level of thyroxin-binding globulin during oral contraception. [Das Verhalten des thyroxinbindenden Globulins, TBG, unter oraler hormonaler Kontrazeption.]
51. Serum lipid alterations associated with the use of oral contraceptive agents. (Abstract only)
52. Serum TSH and serum T3 levels during normal menstrual cycles and during cycles on oral contraceptives.
53. The setting for population/family planning activities in Subsaharan Africa.
54. Sex education, contraception are urgent for teens; premarital pregnancy, illegitimate births increasing.
55. 'Rap' session with teenagers improves knowledge of contraception, abortion, VD.
56. The 1973 abortion material - Contraceptive techniques and postoperative complications. [Aborter ar 1973 i Linkoping - preventivteknik och postoperativa komplikationer.]
57. 2. Voluntary abortion and resistance to contraception. [2. Avortement volontaire et resistance a la contraception.]
58. 33% wanting abortions can't get them. Planned parenthood group accuses hospitals.
59. 47 states permit unwed 18-year-olds to obtain their own birth control services.
60. Abnormal patency of eustachian tube from oral contraceptives. (Letter to the editor)
61. Abortion and contraception information during the first period under new legislation. [Abort- och preventivmedelsradgivning under forsta kvartalet med ny lagstiftning.]
62. Abortion and contraception: a minor's constitutional right to privacy.
63. Abortion in a planned parenthood affiliate: a case study.
64. Abortion: no substitute for contraception.
65. Abortive and contraceptive techniques. [Les techniques abortives et contraceptives.]
66. Acanthosis nigricans following use of oral contraceptives. (Letter to the editor)
67. Acceptability of several methodical principles of oral contraception. [Zur akzeptabilitat verschiedener methodischer Prinzipien der oralen Kont razeption.]
68. The accessories of contraception. [Les accessoires de contraception.]
69. Acquisition of literature population and family planning libraries in developing countries.
70. Actinomycosis infections associated with intrauterine contraceptive devices.
71. Action and efficacy of systemic contraceptive agents, and introduction of complications.
72. The action of hormonal contraceptives on gonadotrophin levels.
73. Action of injectable hormonal contraceptives on the endometrium of the Rhesus monkey) [Accion de los contraceptives hormonales de deposito sobre el endometrio de la mona Rhesus.]
74. Action of prolonged-action contraceptives on the ovaries of rhesus monkeys. [Accion de los contraceptivos de depositio sobre el ovario de la mona rhesus.]
75. Acute arterial occlusion and the contraceptive pill.
76. Acute coronary artery disease and oral contraceptives.
77. Arizona Family Planning Council -- an introduction and invitation.
78. Asia offers limited contraceptive choices.
79. Asian Regional Seminar on the Role of Labour Administrations in Population Education and Family Planning in the Organised Sector, Bangkok, Thailand, November 26-December 1, 1975. Report.
80. Asians bring family planning to factories.
81. Assessing rare and delayed side-effects of contraceptive steroids.
82. Assessment of contraceptive effectiveness in Phase 2 clinical trials.
83. Assessment of national family planning programs in developing countries.
84. Assessment of the toxicity of delivery systems for injectable contraceptives.
85. Assessment of vitamin B6 status. Studies on pregnant women and oral contraceptive users.
86. Association between oral contraceptive use and thromboembolism: a new approach to its investigation based on plasma fibrinogen chromatography.
87. Association between perinatal/infant mortality and family planning in rural Georgia.
88. At the foot of the volcano: Albay Family Planning Project.
89. Attempt of family planning integration in the basic sanitary services in Tunisia. [Essai d'integration du planning familia dans les services sanitaires de base en tunisie. Essai d'integration du planning familial dans les services sanitaires de base en Tunisie.]
90. The attitude of responsible Tunisians toward family planning policy (an attempt at a content analysis of newspaper articles from 1963 to 1974) [L'attitude des responsables Tunisiens vis-a-vis de la politique de planning familial.]
91. Attitude of some elites towards introduction of abortion as a method of family planning in Bangladesh.
92. Attitude of the physician toward contraception. [Actitud del medico ante la anticoncepcion.]
93. Attitude to birth control.
94. Attitudes affecting family planning behaviour among villagers in the Kathmandu Valley of Nepal.
95. Attitudes of men toward contraception.
96. Attitudes of some elites towards introduction of abortion as a method of family planning in Bangladesh.
97. Attitudes of women college students in Seoul towards population and family planning (author's transl)
98. Attitudes to family planning in an aboriginal rural community before the development of a family planning service.
99. Attitudes toward family planning, marriage, and family size among unmarried women in Korea.
100. Attitudes toward family planning: birth control, sterilization and abortion.
101. Attitudinal ambivalence and choice of contraceptive method.
102. Audio-visual resources for population education and family planning.
103. A background note on population, labour and family planning.
104. Bangladesh. (Family planning programs)
105. A basic plan to teach family planning in the schools of medicine. [Plan basico: para la ensenanza de la planificacion familiar en las facultades, escuelas, de medicina.]
106. Behavioral components influencing use effectiveness of family planning by prediction of ovulation (Billings method)
107. Benign hepatoma and oral contraceptives.
108. Bibliography (on birth control and the black American)
109. Bibliography of family planning materials.
110. Bibliography on human reproduction, family planning and population dynamics: annotated articles and unpublished work in the South-East Asia Region, April 1974-September 1974.
111. Bibliography on human reproduction, family planning and population dynamics: annotated articles and unpublished work in the South-East Asia Region, October 1974-January 1975.
112. Bibliography on human reproduction, family planning and population dynamics: annotated articles and unpublished work in the South-East Asia Region.
113. Bibliography on human reproduction, family planning and population dynamics: annotated articles and unpublished work in the South-East Asia Region: family planning programmes (including review of current status)
114. Bibliography on human reproduction, family planning and population dynamics: annotated articles and unpublished work in the South-East Asia Region: male reproduction and Fertility Control (including review of current status)
115. Bibliography on human reproduction, family planning and population dynamics: annotated articles and unpublished work in the Southeast Asia Region: intrauterine contraceptive devices.
116. Billing's Method of Family Planning.
117. Biochemical changes in the fallopian tube and uterus of the rhesus monkey (Macaca mulatta) under the influence of progestational contraceptive steroids.
118. Biochemical studies with once-a-month contraceptive pill containing quinestrol-quingestanol acetate.
119. Biochemistry and the selection of oral contraceptives.
120. Biological effectiveness of temperature and rhythm birth control. Final report to Human Life Foundation.
121. The biological effects of contraceptives: Studies on the female rabbit. [Les effets biologiques des antigestatifs: Tests d'etude chex la lapine.]
122. Birth control and social environment. [Geburtenregelung und soziale Umwelt.]
123. Birth control as black genocide - fact or paranoia?
124. Birth control in the early Byzantine Empire.
125. Birth control techniques in Africa. [Techniques de regulation des naissances en Agrique.]
126. Birth control: arguments.
127. Birth control: background.
128. Birth control: How is it practiced?
129. Birth control: religion.
130. Birth politics: yes; anticontraceptive politics: no. [Politique de natalite: oui; politique anti-contraception: non.]
131. Blastocidal and contraceptive actions of saponins from phytolacca dodecandra L. (Abstract only)
132. Blastocyst surface ultrastructure as a tool in contraceptive research.
133. Bone mineral: effects of oral contraceptives, pregnancy, and lactation.
134. Brazil. (Family planning programs)
135. Breast cancer and oral contraception. (Editorial)
136. Breast-feeding and oral contraceptives. [Allaitement maternel et contraceptifs oraux.]
137. Brief overview of the Indonesian family planning program.
138. A brief review of the National Family Planning Programme with special reference to industries.
139. A brief summary of the community-based distribution of contraceptives project in Korea.
140. C-Film as a contraceptive.
141. C-film contraceptive: trial results disputed.
142. Can sterilization be regarded from the legal aspect as irreversible contraception? [Je z pravniho hlediska spravne pokladat sterilizaci za irreverzibilni antikoncepci?]
143. Cancer detection and contraception.
144. Carbohydrates, brain metabolism and contraceptive-induced depression. (Letter to the editor)
145. A case of pregnancy and labor with an intrauterine contraceptive device. [Przypadek ciazy i porodu z srodmaciczna wkladka antykoncepcyjna.]
146. A cast of 40: population and family planning agencies at work in the Philippines.
147. Catalogue of training opportunities on population and family planning.
148. The Catholic church and birth control: Curacao and Puerto Rico.
149. Catholics and contraceptives: attitudes and practice.
150. CBD (Community based distribution (of contraceptives)) project status report.
151. Cell mediated immunity in healthy women taking oral contraceptives.
152. Cell-mediated immune response in mice treated with steroidal contraceptives.
153. Central effects of the depot-gestagens norgestrel capronate and norgestrel undecylate and their appropriateness as long-term contraceptives.) (Abstract only. [Untersuchungen uber die zentrale Wirkung der Depot-Gestagene Norgestrelc apronat und Norgestrelundecylat und ihre Eignung als Langzeitkontrazepti va.]
154. Cerebrovascular accidents after taking oral contraceptives. Eight cases.) (Letter to the editor. [Accidents vasculaires cerebraux apres prise de contraceptifs oraux. Huit observations.]
155. Cerebrovascular accidents and oral contraceptives (reflections concerning 36 cases) [Accidents vasculaires cerebraux et contraceptifs oraux--reflexions a propos de 36 observations.]
156. Cerebrovascular lesions and oral contraceptives. [Cerebrovaskulara lasioner och orala kontraceptionsmedel.]
157. Cerebrovascular strokes after oral contraceptives. [Accidents vasculaires cerebraux apres contraceptifs oraux.]
158. Cervical gonorrhea in women using different methods of contraception.
159. Change and differentials in women's knowledge of, attitude towards and practice of family planning in Pakistan during the 1960s.
160. Changes in biochemical indices of vitamin nutrition in women using oral contraceptives during treatment with "Surbex 500."
161. Changes in breast volume during normal menstrual cycle and after oral contraceptives.
162. Changes in carbohydrate tolerance during long-term oral contraception.
163. Changes in contraceptive knowledge, attitudes, and behavior of college students.
164. Changing attitudes in favour of family planning.
165. Changing concepts of intrauterine contraception.
166. Child health--the keystone of family planning.
167. Children's accidents by ingestion of contraceptives. [Ingestionsunfalle mit Ovulationshemmern bei Kindern.]
168. Chile. (Family planning programs)
169. China, the People's Republic of. (Family planning programs)
170. Choice of contraceptive method.
171. Choice of contraceptives.
172. Chromosome breakage studies in lymphocytes from normal women, pregnant women, and women taking oral contraceptives.
173. Chromosome examinations following treatment with contraceptive pills produced in Hungary.
174. Chromosomes and oral contraceptives: aberrations in relation to neoplasia.
175. Circulating hormones, EEG, and performance in psychological tests of women with and without oral contraceptives.
176. Clinical and biological study of a low-dosage oral contraceptive containing only 30 mcg of ethinyl estradiol. [Etude clinique et biologique d'un contraceptif oral minidose ne contenant que 30 mcg d'ethinyl estradiol.]
177. A clinical appraisal of patients following long-term contraception.
178. Clinical assessment of subdermal implants of megestrol acetate, d-norgestrel, and norethindrone as a longterm contraceptive in women.
179. Clinical complications of oral contraceptives.
180. Clinical complications of oral contraceptives.
181. Clinical evaluation of a new contraceptive, "Pregnon."
182. Clinical evaluation of a new oral contraceptive, "Pregnon."
183. Clinical evaluation of a new oral contraceptive: Ovostat. [Evaluation clinique d'un nouveau contraceptif oral: Ovostat.]
184. Clinical evaluation of C-film, a vaginal contraceptive.
185. Clinical experience with ethinyl estradiol and d-norgestrel as an oral contraceptive.
186. A clinical impression of a combination-type contraceptive: Neo-Lyndiol.
187. Clinical investigation of medroxyprogesterone acetate and estradiol cypionate in contraceptive injection administered monthly. [Investigacion clinica de medroxiprogesterona y cipionato de estradiol en inyeccion mensual anticonceptiva.]
188. Clinical research on a normophasic oral contraceptive. [Klinische Untersuchung eines oral wirksamen, normophasischen Kontrazeptivums.]
189. Clinical results with a new low dose oral contraceptive utilizing norethindrone/ethinyl estradiol.
190. Clinical study of a low dose contraceptive combination of 0.030 g--sic--of ethinyl estradiol and 1 mg norethisterone acetate. [Etude clinque d'une association contraceptive minidosee comportant 0.030 g--sic--d'ethinyl-oestradiol et 1 mg d'acetate of norethisterone.]
191. Clinical study of a progesterone-releasing intrauterine contraceptive device.
192. Clinical study of Restovar. Oral Contraceptive with low estrogen dose. [Etude clinique de Restovar. Contraceptif oral a faible teneur oestrogene.]
193. Clinical study on the normophasic oral contraceptive Ovanone. (Abstract only)
194. Clinical trial of a low dose combined oral contraceptive ("Ovranette")
195. Clinical trial of a new oral contraceptive with a low oestrogen dosage: Restovar.
196. Colombia (Family planning programs)
197. Colombia. (Can patients be educated in a clinic about family planning?)
198. Colposcopic findings during hormonal contraception. [Kolposkopische Befunde bei hormoneller Kontrazeption.]
199. A colposcopy referral service for family planning clinics.
200. Combination contraceptive effects on monthly cycle of plasma aldosterone, renin activity and renin substrate.
201. Combined contraceptive therapy by monthly parenteral administration of small doses. [Terapia anticonceptiva combinada a dosis baja en administracion parenteral mensual.]
202. Combined use of steroid preparations and antiadrenergic substances for contraceptive purposes. [O sochetannom primenenii steroidnikh preparatov i antiadrenergicheskikh veshestv s tseliyu kontratseptsii.]
203. (Comments on post-coital contraception. J. 9)
204. Commercial contraceptive marketing development in Bangladesh. Annual report, June 20, 1974-June 20, 1975.
205. The commercial contraceptive marketing program: a progress report.
206. Commission on health of the Chamber of Representatives: analysis of contraceptives. [Comissao de saude da camara dos deputados: analisa anticoncepcionais.]
207. Communication in family planning.
208. Communication media, family planning and development.
209. Communication principles in family planning.
210. Communication research in family planning: an analytical framework.
211. Communications activities that promote behavior change in clients of family planning programs: resources and constraints.
212. Community education programme for family planning in Hawaiian-Philippine Company.
213. Community resource mobilization for family planning. Rio grande do norte Brasil.
214. Community-based distribution of contraceptives in Japan.
215. Community-based distribution of contraceptives.
216. Community-based distribution of contraceptives: a system for program monitoring and basic evaluation.
217. Community-based distribution of oral contraceptives in Rio Grande do Norte, Northeast Brazil.
218. Community-based successes. (Contraception)
219. Comparative catamnestic studies of women's psychological reactions to sterilization and to long-term treatment with ovulation inhibitors for family planning. [Psychische Verarbeitung der Sterilisation bei Frauen und der Langzeitein nahme von Ovulationshemmern im Rahmen der Familienplanung; vergleichende katamnestische Untersuchungen.]
220. Comparative studies of the ethynyl estrogens used in oral contraceptives. 2. antiovulatory potency.
221. Comparative studies of the ethynyl estrogens used in oral contraceptives: 1. endometrial response.
222. Comparative studies of the ethynyl estrogens used in oral contraceptives: effect on plasma gonadotropins.
223. A comparative study of family planning service statistics systems in the ESCAP region.
224. A comparative study on the administration of family planning programmes in the ESCAP region: organizational determinants of performances in family planning services in selected ESCAP countries: Singapore national study.
225. Comparison of changes in some blood coagulation tests caused by use of three oral contraceptives. First symposium -- sex steroids. [Comparacion de la modificacion en algunas pruebas of coagulacion por el uso de tres anticonceptivos orales. Primer simposio -esteroides sexuales.]
226. Comparison of chromosome breakages in lymphocytes and fibroblasts from control women and women taking oral contraceptives.
227. A comparison of event rates in nulligravid and nulliparous women using the small Dalkon shield for intrauterine contraception.
228. Complications of intrauterine contraceptive devices.
229. Complications of oral contraception. [Les accidents de la contraception orale.]
230. Complications of oral contraceptive agents: a symposium.
231. Complications of pregnancy with an intrauterine contraceptive device in situ.
232. Complications of systemic contraceptive agents: hypertension.
233. Complications of systemic oral contraceptive therapy: neoplasm - breast, uterus, cervix and vagina.
234. The comprehensive family planning services program for nurses and midwives: the Philippine experience.
235. Comprehensive family planning services to an urban black community.
236. Conception and contraception in the lactating mother.
237. Concerning individualized dosages of contraceptive steroids. [Zur individuell angepassten Dosierung kontrazptiver Steroide.]
238. Conclusion. (Demographic evaluation of family planning programs)
239. Condoms and contraception. [Preservatifs masculins et contraception.]
240. Conducting a family planning meeting.
241. Congress adds $12 mil. to population research grants pot; for 1976; contraceptive development, behavioural sciences contract work set.
242. Congress votes 'yes' on health services bill; family planning legislation extended to FY 1977.
243. Conjugal role structure, joint action, and contraception adoption.
244. Construction and standardization of two scales of marital adjustment and attitude towards family planning.
245. Construction of a statistical and epidemiological model in the field of family planning.
246. Consultant report on commercial contraceptive distribution in Bangladesh.
247. Consumers' perceptions of patient-package inserts for oral contraceptives. Appendix 1.
248. Content of cholesterol in pre-beta and beta lipoprotein fractions of blood serum and total cholesterol concentrations in women ingesting progestagen preparations as contraceptives. [Zawartosc cholesterolu we frakcjach pre-beta i beta liproteidowych surowicy oraz stezenie cholesterolu ogolnego u kobiet stosujacych preparaty gestogenowe w celach antykoncepcyjnych.]
249. Contraception - some non-users.
250. Contraception and birth defects. [Kontrazeption und Birth Defects.]
251. Contraception and cervical colonization with mycoplasmas and infection with cytomegalovirus.
252. Contraception and sperm transport in domestic animals.
253. Contraception and sterility. [Contraception et sterilite.]
254. Contraception and subsequent fertility. A general review on the reversibility of oral contraception. [Contraception et fertilite ulterieure. Revue generale sur la reversibilite de la contraception orale.]
255. Contraception and the fantasy of coitus uninterruptus. [Contraception et fantasme du coit ininterrompu.]
256. Contraception and the general practitioner.
257. Contraception and the youths at Rennes University. [La contraception et les jeunes de l'universite de Rennes.]
258. Contraception and venereal diseases. [Contraception et maladies veneriennes.]
259. Contraception at the time of intercourse. [La contraception contemporaine du rapport sexuel.]
260. Contraception by injection of a depot gestagen every three months. [La limitazione delle nascite con iniezione trimestrale di progestinici deposito.]
261. Contraception by injection.
262. Contraception by intrauterine device. [Contraception par dispositif intra-uterin.]
263. Contraception by intrauterine release of progesterone: clinical results.
264. Contraception by intrauterine release of progesterone: effects on endometrial trace elements, enzymes and steroids.
265. Contraception by intrauterine release of steroids.
266. Contraception explained.
267. Contraception for the teenagers.
268. Contraception for the woman with significant cardiac disease.
269. Contraception in adolescence.
270. Contraception in adolescence. (Abstract only)
271. Contraception in adolescence: a review of the literature.
272. Contraception in cardiac cases.
273. Contraception in males: January 1973 through November 1975. (142 citations))
274. Contraception in nulliparous women. [La contraception chez la nullipare.]
275. Contraception in Rennes. Studies of data from the Center of Health Surveys. [La contraception a Rennes. Etudes de donnees du Centre d'Examens de Sante.]
276. Contraception in the postpartum and postabortion periods. [La contraception dans le post-partum et le post-abortum.]
277. Contraception in vascular diseases. [Kontrazeption bei Gefasskrankheiten.]
278. Contraception today and tomorrow.
279. Contraception with IUDs.
280. Contraception with methods of intrauterine release of progesterone. [Anticoncepcion con sistemas de liberacion intrauterina de progesterona.]
281. Contraception, abortion and venereal disease: teenagers' knowledge and the effect of education.
282. Contraception, marriage, and sexual relations in the Christian west.
283. Contraception.
284. Contraception.
285. Contraception: current status of hormonal agents.
286. Contraception: past, present and future.
287. The contraceptive action of lynestrenol phenylpropionate.
288. Contraceptive activity of combinations of steroid and antiadrenergic preparations. [O kontraceptivnoi aktinvosti sochetanii steroidikh i antiadrenergich eskikh preparatov.]
289. Contraceptive aids. [Les accessoires de contraception.]
290. Contraceptive continuation of hospitalized psychiatric patients.
291. The contraceptive dilemma in adolescents. The birth control pill versus the intrauterine device. (Abstract only)
292. Contraceptive effect of 0.1 and 0.125 mg of norethindrone twice a day. [Efecto anticonceptivo de noretindrona 0.1 y 0.125 mg dos veces al dia.]
293. Contraceptive effect of ethylnorgestrienone in men and women. The unisex pill. [Efeito contraceptivo da ethy l norgestrienone em homens e mulheres. A pilula unisex.]
294. Contraceptive effect of gestagens.
295. Contraceptive effectiveness in Belgium. Results of the national inquiry Family Development 1971. (NEGOII) [Effectiviteit van anticonceptie in Belgie. Resultaten van de nationale enquete Gezinsontwikkeling 1971. (NEGO II)]
296. Contraceptive effectiveness of sequential preparations. [Contraceptieve betrouwbaarheid van sequentiepreparaten.]
297. Contraceptive effectiveness of silastic implants containing the progestin R-2323.
298. Contraceptive efficiency. Reflections on statistical evaluation and real value. [Efficacite de la contraception. Reflexions sur son evaluation statistiqu e et sa valeur reelle.]
299. Contraceptive information to puerpural women.) (Letter to the editor. [Prevensjonsveiledning til barselkvinner.]
300. Contraceptive inundation: Pakistan saturates market to control births.
301. Contraceptive methods and side effects.
302. Contraceptive nonconformity among Catholics.
303. Contraceptive pill amenorrhea - does it e xist? [P-pilleramenorre - finns den?]
304. The contraceptive pill and myocardial infarction. [P-piller og hjerteinfarkt.]
305. Contraceptive pills and myocardial infarction. [P-pillen og myokardinfarkt.]
306. Contraceptive practice and prevention as an alternative to the legalization of indiscriminate abortion. [La pratica contraccettiva e la profilassi come alternativa alla legittimazione dell'aborto indiscriminato.]
307. Contraceptive practice and unplanned pregnancy among single university students.
308. Contraceptive practice and unplanned pregnancy in students. (Letter to the editor)
309. Contraceptive practice in the context of a nonrestrictive abortion law: age-specific pregnancy rates in New York City, 1971-1973.
310. Contraceptive properties of danazol.
311. Contraceptive services family planning programs Western Hemisphere Region.
312. Contraceptive services for adolescents; United States, each state and county, 1975.
313. Contraceptive sterilization: use-prevalence and acceptability (societal and individual)
314. Contraceptive steroid binding to the human uterine progesterone-receptor.
315. Contraceptive steroids and hypertension.
316. Contraceptive techniques.
317. Contraceptive technology and population planning.
318. Contraceptive technology in controlling reproduction in pets.
319. Contraceptive usage and its relationship to wanted or unwanted pregnancy.
320. Contraceptives and lipid metabolism.
321. Contraceptives and pseudocholinesterase medicamental interference.
322. Contraceptives for males.
323. Contraceptives for the teen-ager: things to know before prescribing.
324. Contraceptives in the Third World.
325. Contrasting effects of combined and sequential oral contraceptives on LH-RH-stimulated release of LH and FSH as compared to minipills. (Abstract only)
326. Contribution of family planning to demographic, economic and social goals. Report presented to the International Planned Parenthood Federation Conference, Brighton, October 1973.
327. Control of oral contraceptive clinical trials.
328. Control of population growth and family planning. (Part 1)
329. Copper IUD, inserted after coitus averts pregnancy and provides continuing contraceptive protection.
330. Correlates of fieldworker performance in the Indonesian Family Planning Programme: a test of the Homophily-Heterophily Hypothesis.
331. Cortisol metabolism after oral contraceptives: total plasma cortisol and free cortisol index.
332. Could contraceptives with progestational effect cause voice changes? [Kunnen contraceptiva met progestatieve werking stemveranderingen veroorzaken?]
333. The coupon system for family planning evaluation.
334. Coverage and quality of urban family planning services rendered through an MCH/FP centre: an evaluatory study.
335. Creative community health planning: an acute general hospital and a family planning affiliate.
336. Cribriform polypoid adenomatous hyperplasia of cervical glands after oral contraceptives. ["Siebartige polypoide Zervixdrusenhyperplasie" nach Oralen Kontrazeptiva.]
337. Criteria for evaluation of the present statistical data reporting systems for management of family planning programs.
338. Criteria for selection of contraceptive methods for the purpose of preventive medicine. [Criteres de selection des modes de contraception dans un but de prevention.]
339. Criterion for contraceptive methods. [Critiers des methodes contraceptives.]
340. The critical estrogen content of combined oral contraceptives.
341. A critical evaluation of the family planning programme and some recommendations.
342. Current state and perspectives of contraceptive methods. [S'vremenno s'stoyanie i perspektivi na kontratseptivnite metodi.]
343. Current status of clinical trials of steroid contraceptives.
344. Current status of female hormonal contraception.
345. Curriculum outline on natural family planning. [Bosquejo curriculum sobre planificacion natural de familia.]
346. Cyclic AMP content of gingival fluid in women taking oral contraceptives.
347. Cyclical variation in Factors 7 and 8 associated with oral contraception.
348. A cytogenetic study in women who had used oral contraceptives and in their progeny.
349. Cytological changes produced by oral contraceptives and IUDs. [Alteraciones citologicas producidas por los anovulatorios y anticonceptivos intrauterinos.]
350. Cytopathologic alterations associated with intrauterine contraceptive de vices. (Abstract only)
351. d-Norgestrel slow-releasing T device as an intrauterine contraceptive.
352. The Dalkon shield contraceptive device in general practice.
353. Data on Costa Rica's National Family Planning Program.
354. Data to the vascular and hepatic complications of oral contraceptives.
355. Dating patterns, sexual relationships and use of contraceptives of 700 unwed mothers during a two year period following delivery.
356. Death risk of pregnancy and family planning practice.
357. Decline in fertility and family planning: an appraisal.
358. Delivering family planning services in rural areas.
359. Demand for family planning in rural Bangladesh.
360. Demographic and socio-economic variations in health and family planning behavior in urban Pakistan.
361. The demographic impact of adding induced abortion to national family planning methods.
362. Demography and contraception, part 2. [Demographie et contraception--2e partie.]
363. Demography and contraception. Part 1. [Demographie et contraception--lre partie.]
364. A demonstration component of the INC Mobile Clinic Program utilizing non -professional volunteers in a community-based distribution of contraceptive supplies.
365. Demonstration of the harmlessness of hormonal contraceptives on subsequent pregnancies. [Beitrag zum Nachweis der Unbedenklichkeit hormonaler Kontrazeptiva auf nachfolgende Schwangerschaften.]
366. Depressions caused by oral contraceptives and their treatment with Origen.
367. DES: its uses and effects as contraceptive and additive.
368. Design of clinical trials for contraceptive steroids. Assessment of efficacy.
369. Design of Phase 1 studies for depot contraceptives.
370. Detection of disease of the breast in women attending a family planning association clinic. (Abstract only)
371. The detection of ovulation in humans and its application in contraception.
372. Determination of fibrinolytic split products during treatment with hormonal contraceptives. [Nachweis von fibrinolytischen Spaltprodukten wahrend der Einnahme von hormonalen Kontrazeptiva.]
373. Developing a family planning communications campaign.
374. Developing a strategy for a family planning communications campaign.
375. Developing and presenting a strategy for training family planning administrators.
376. Development of a scale to measure elementary school teachers' attitudes toward contraceptive education.
377. The development of adenocarcinoma of the endometrium in young women receiving long-term sequential oral contraception: report of four cases.
378. Development of an educational model in family planning.
379. Development of an instrument to measure attitudes toward the personal use of premarital contraception.
380. The development of depot contraceptives.
381. The development of graduate studies for health education in family planning at the University of the West Indies.
382. Development of the oral contraceptives. (Letter to the editor)
383. Development of the profamilia rural family planning program in Colombia.
384. Development trends in family planning using hormones and hormone combinations. [Trendentwicklung der Familienplanung mit Hormonen und Hormonkombinatione n.]
385. DFT's family planning and population planning activities (summary)
386. Die kontinuierliche postpartale Verabreichung von Quingestanolazetat 0,3 mg als Kontrazeptivum. (Continuous postpartal administration of quingestanol acetate (0.3 mg) as a contraceptive)
387. Diethylstilbestrol as postcoital oral contraceptive (Federal Register 40(25): 5351-5355, February 5, 1975)
388. Diethylstilbestrol as postcoital oral contraceptive; patient labeling.
389. Differences in predominant family planning attitudes and experiences of seminary students: a ten-year assessment.
390. Differential effects of ethinylestradiol (EE) vs norethindrone (nor-T) upon glucagon secretion in relation to contraceptive-lipemia.
391. The differential evaluation of large and small families in rural Colombia: implications for family planning.
392. Differentials in fertility, family planning practice, and family size values in South Korea, 1965-1971.
393. Differentials in the adoption of oral contraceptives.
394. Differentiated contraception with 2 low-dose ethinyl estradiol-norethisterone combinations. [Differenzierte Kontrazeption mit zwei niedrig dosierten Athinylostradiol -Norethisteron-Kombinationen.]
395. Differentiation of Factor C-LHIH and the synthetic contraceptive polypeptide, H-Thr-Pro-Arg-Lys-OH.
396. Diffusion of new models for behaviour: implications for research in the field of family planning. [La diffusione dei nuovi modelli di comportamento: implicazioni per la ricerca nel campo della pianificazione familiare.]
397. Dinitrochlorobenzene sensitization test in women on hormonal contraceptives.
398. Direct evaluation of the effect of use of oral contraceptives on fertility.
399. Discussion. (Family planning)
400. Distribution and supervision of oral contraceptives.
401. The doctor and society: contraception for minors.
402. The doctors role: selected articles on family planning and population by Dr. D. Malcolm Potts.
403. Documentation in the field of human reproduction, family planning and population dynamics. Report of a seminar, New Delhi, April 28-May 2, 1975.
404. Documents for the final report and recommendations meeting of the International Contraceptive Study Project, (ICOSP), Palais des Nations, Geneva, September 22-23, 1975.
405. Domiciliary family planning.
406. Dominican Republic. (Family planning programs)
407. Drug and patient matching for safer oral contraception.
408. Drug delivery systems in contraception.
409. Drug interactions 1: meperidine and combination oral contraceptives.
410. Dutch Catholics on birth control and sexuality.
411. Early reconception and contraceptive use among black teenage girls after an illegitimate birth.
412. East Asia 1974: an overview. (Family planning programs)
413. East Asia shares experience in family planning: field notes.
414. Econometric estimation of the benefits of family planning in India.
415. Ectopic pregnancy despite intrauterine contraception: a clue to mode of action of I.U.C.D.s.
416. Effect of a copper intra-uterine contraceptive device on sub-cellular distribution and concentration of copper in the rat uterus. (Letter to the editor)
417. Effect of a copper intrauterine contraceptive device and nylon suture on the estradiol 17beta-6,7-tritiated and progesterone 1,2-tritiated in the rat uterus.
418. Effect of a copper intravas-contraceptive device on biochemistry of epididymis and vas deferens in male rats.
419. Effect of a copper-containing intrauterine contraceptive device on Neisseria gonorrhoeae in vitro.
420. The effect of an oral contraceptive on acid-base balance, blood gases, and electrolytes.
421. Effect of assortative mating and family planning on the incidence of unisexual sibships.
422. The effect of combination and low dose progestogen oral contraceptives on serum lipids.
423. Effect of contraception and abortion on fertility.
424. Effect of contraceptive hormonal steroids on the cardiovascular system of dogs: scanning electron microscopic studies of arteries and veins. (Abstract only)
425. The effect of contraceptive hormones on the gingival tissue of the rat.
426. Effect of contraceptive steroids on arginine-stimulated glucagon and insulin secretion in women: I-lipid physiology.
427. Effect of contraceptive steroids on serum lipids.
428. Effect of different oral contraceptives on the female reproductive system. (Abstract only)
429. Effect of estrogen-containing oral contraceptives on urinary corticosteroid sulfate excretion.
430. Effect of ethynodiol diacetate and combination-type oral contraceptive compounds on carbohydrate metabolism.
431. The effect of hormonal contraceptives on the plasma fibrinolytic activity of black women. (Abstract only)
432. Effect of intrauterine contraceptives on the childbearing functions of women and the state of the children (Abstract only) [Vliyanie vnutrimatochnikh kontratseptivov na detorodnuyu funktsiyu zhenschin i sostoyanie detei.]
433. Effect of local infection and oral contraception on immunoglobulin levels in cervical mucus.
434. Effect of long-term therapy with an oral contraceptive on some aspects of hepatic lipid metabolism in vitro.
435. Effect of oral contraceptive agents on nutrients: 2. Vitamins.
436. Effect of oral contraceptive agents on nutrients: I. Minerals.
437. Effect of oral contraceptive agents on the metabolism of some trace minerals.
438. Effect of oral contraceptive agents on vitamin nutrition status.
439. The effect of oral contraceptive estrogen on blood coagulation and fibrinolysis.
440. The effect of oral contraceptive steroids on the response of thyroid-stimulating hormone to thyrotropin-releasing hormone.
441. Effect of oral contraceptives and IUD's on the copper in human cervical mucus.
442. Effect of oral contraceptives and pregnancy on erythrocyte deformability and surface charge (39037)
443. Effect of oral contraceptives and pyridoxine on the metabolism of Vitamin B6 and on plasma tryptophan and alpha-amino nitrogen.
444. Effect of oral contraceptives and Vitamin B6 deficiency on carbohydrate metabolism.
445. The effect of oral contraceptives on folate metabolism: 3. Plasma clearance and urinary folate excretion.
446. Effect of oral contraceptives on plasma clearance.
447. Effect of oral contraceptives on plasma lipoproteins, cholesterol and alpha-tocopherol levels in young women.
448. Effect of oral contraceptives on some metabolisms. [Etude du retentissement de la contraception orale sur divers metabolismes.]
449. The effect of oral contraceptives on the concentration of some salivary substances in women.
450. The effect of oral contraceptives on uterine size examined by ultrasound. (Abstract only)
451. Effect of Ovral, a combination type oral contraceptive agent, on Vitamin A metabolism in rats.
452. Effect of selective lesioning of brain serotonin or catecholamine-containing neurons on the activity of oral steroid contraceptives in rats.
453. Effect of sex, oral contraceptives, and glucose loading on apomorphine-induced growth hormone secretion.
454. The effect of uniform medical standards on the provision of contraceptive services in the state of Illinois.
455. Effective communication on population questions and family planning in the organised sector.
456. Effectiveness of a contraceptive education program for postabortion patients in Chile.
457. Effectiveness of abortion as birth control.
458. Effectiveness of family planning programme in rural areas: a cross-sectional study.
459. Effects of a progestogen and a sequential type oral contraceptive on plasma Vitamin A, Vitamin E, cholesterol and triglycerides.
460. Effects of chronic administration of contraceptive steroids on the biological age of rat ovarian cycles after discontinuing treatment. [Effet de l'administration chronique de steroides anticonceptionnels sur l'age biologique des cycles ovariens de la ratte apres arret du traitement.]
461. Effects of chronic oral contraceptive (OC) treatment on growth and activity of microsomal drug metabolizing enzymes in protein malnourished rats. (Abstract only)
462. Effects of chronic oral contraceptive treatment on the conversion of angiotensin I to angiotensin II in the rat.
463. Effects of family planning programs (EFPP)
464. Effects of low dose oral contraceptives containing norethindrone and ethinyl estradiol on serum levels of progesterone and pituitary gonadotropins.
465. Effects of low-dose lynestrol as a contraceptive.
466. Effects of lynestrenol, used alone in low doses as a contraceptive. [Efectos del linestrenol utilizado solo a dosis baja, como anticonceptivo.]
467. Effects of oral contraceptive agents (OCA) on platelet (P) function. (Abstract only)
468. Effects of oral contraceptive agents on carbohydrate metabolism.
469. Effects of oral contraceptive steroids on transport of plasma lipids in the fed state. (Abstract only)
470. Effects of oral contraceptive steroids on vitamin and lipid levels in serum.
471. Effects of oral contraceptive therapy on the circadian patterns of cortisol and thyrotropin (TSH)
472. Effects of oral contraceptives on tryptophan metabolism and vitamin B6 requirements in women.
473. Effects on serum complement of normal and pre-eclamptic pregnancy and of oral contraceptives.
474. Egypt. Family planning programs.
475. Electromicroscopical aspects of endometrial distrophy induced by oral contraceptives. [Aspectos electromicroscopicos de la distrofia endometrial producida por anticonceptivos orales.]
476. Eliazbethan birth control and Puritan attitudes.
477. Elizabethan birth control and Puritan attitudes.
478. Emerging role of the physician and other family planning health workers in community-based family planning services.
479. Endometrial carcinoma in young women taking oral contraceptive agents.
480. Endometrial effects of estrogen-progestogen contraceptive preparations at different dose levels. [Effets endometriaux des associations oestro-progestatives contraceptives a differents niveaux de dosage.]
481. ESCAP study on family planning administration in the Republic of Korea: interpretive summary.
482. Estrogen potency of oral contraceptive pills.
483. The estrogen-progestagens or hormonal contraception. [Les oestro-progestatifs ou la contraception hormonale.]
484. A review of family planning and MCH programme in Nepal.
485. Rhodesia (family planning)
486. The rhythm method of contraception.
487. Risk of myocardial infarction in users of oral contraceptives.
488. The role of a national association for voluntary sterilization in the national family planning program.
489. The role of breast feeding in family planning.
490. The role of Continuin in Contraception. [A Continuin helye a fogamzasgatlasban.]
491. The role of employers and their organisations in population and family planning in industry.
492. The role of health survey research in maternal and child health/family planning programmes: Danfa Project, Ghana.
493. The role of husband-wife communication in family planning.
494. The role of medical students and youth in family planning and population programme.
495. The role of medical students and youth in family planning and population programme.
496. The role of medical students and youth in family planning and population programme.
497. Sex education, contraception seen urgent for teenagers as premarital pregnancy, illegitimate births increase.
498. Sexual and contraceptive factors in birth planning success.
499. Sexual and contraceptive knowledge, attitudes and behavior of male adolescents.
500. Sexual counseling in a family planning clinic: the challenge to staff.